ZC0109 is a dual inhibitor ofIDO1andthioredoxin reductase 1(TrxR1) withIC₅₀s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads tocancercellsapoptosis^[1].

IC50: 50 nM (IDO1), 3.0 μM (TrxR1)^[1]

ZC0109 (24 h) inhibits cancer cells with IC₅₀s of 3.44 μM (HCT-116), 12.4 μM (CT26), and 10.2 μM (HeLa), respectively^[1].
ZC0109 (2.5-10 μM; 24 h) induces ROS accumulation in HCT-116 and HeLa cells^[1].
ZC0109 (2.5-10 μM; 24 h) induces apoptosis and G1/S cell cycle arrest in cancer cell^[1].

ZC0109 (15, 30, and 60 mg/kg; p.o.; once daily for 28 d) reduces Kyn/Trp metabolism in C57BL/6 mice^[1].
ZC0109 (60 mg/kg; p.o.; once daily for 28 d) decreases tumor growth and increases accumulation and infiltration of T cells in CT-26 cells transplanted immunocompetent BALB/c mice^[1].

591.41

C₂₂H₂₀BrFN₈O₄S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.